II-CVHAP.gif (16582 bytes)

APLICACIÓN DE LAS TÉCNICAS INMUNOHISTOQUÍMICAS AL ESTUDIO DE LOS SÍNDROMES LINFOPROLIFERATIVOS

  Dr. Tomás Álvaro Naranjo, Dr. Ramón Bosch Príncep, Dra. Salomé Martínez González, Dra. Mª Teresa Salvadó Usach  

Comentarios


12.- Bibliografía

Volver al Índice



Bibliografía

  1. Alavaikko MJ, Blanco G, Aine R, Lehtinen T, Fellbaum C, Taskinnen PJ, Sarpola A, Hansmann ML. Follicular dendritic cells have prognostic relevance in Hodgkin's disease. Am J Clin Pathol 1994;101:761-767.
  2. Álvaro Naranjo T, ed. 1er Curso de Hematopatología. Tortosa: Inst Cat Salut, 1994.
  3. Álvaro Naranjo T, ed. 2º Curso de Hematopatología. Tortosa: Inst Cat Salut, 1995.
  4. Álvaro T. Factores técnicos en el estudio de síndromes linfoproliferativos. En: Álvaro Naranjo, Segundo Curso de Hematopatología, Tortosa, Inst. Cat. Salut, 1995.
  5. Alvaro T, Font L, Contreras E, Gonzalez S, Izuel JA, Sirvent JJ. Linfoma de alto grado de malignidad de tejido linfoide asociado a las mucosas del estómago. Patología 1995; 28: 265-269.
  6. Álvaro T, Bosch R, Salvadó MT, Piris MA. True histiocytic lymphoma of the stomach associated with low-grade B-cell Mucosa Associated Lymphoma tissue (MALT)-Type lymphoma. American Journal of Surgical Pathology. 1996: 20: 1406-1411.
  7. Álvaro-Naranjo T, Salvadó-Usach MT, Bosch-Príncep R, Martínez-González S. P53 en enfermedad de Hodking. Med Clin (Barc) 1996; 10: 398-399.
  8. Alvaro-Naranjo T, Salvadó-Usach T, Font-Ferré L, Gumà-Padrò J, Bosch-Príncep R, Contreras-Barbeta E.Significado pronòstico de la proteína P53 en la enfermedad de Hodgkin. Neoplasia 1996;13:1-4.
  9. Álvaro T; Salvadó Mt; Martínez S; Bosch R; Risa R; Barberá M. Desenmascaramiento antigénico no enzimático. Estudio comparativo entre horno microondas y olla a presión en secciones de tejido fijadas en formol e incluidas en parafina. PATOLOGÍA 1996; 29: 217-225.
  10. Álvaro T, Bosch R, Martínez S, Salvadó MT ed.  Tercer Curso de Hematopatología. Tortosa: Inst Cat Salut, 1996.
  11. Álvaro T; Piris MA; Campo E. Factores técnicos, de estudio y de diagnóstico aplicados a la patología linfoide. Encuesta a 47 patólogos españoles. PATOLOGIA 1996; 29:319-324.
  12. Álvaro Naranjo T., editor. Tercer Curso de Hematopatología, edición multimedia en CD-ROM. Tortosa, Inst. Cat. Salut, 1996.
  13. Álvaro Naranjo T., editor. Cuarto Curso de Hematopatología, edición multimedia en CD-ROM. Tortosa, Inst. Cat. Salut, 1997.
  14. Álvaro T. Metodología de trabajo en el estudio de síndromes linfo- y mieloproliferativos. Errores más comunes, sus consecuencias y forma de corregirlos. Tutorial de Patología Linfoide, Sevilla, 1997; 1: 26-43.
  15. Álvaro T, Font Ll, Bosch R, Salvadó MT, Guma J, ed.  Cuarto Curso de Hematopatología. Tortosa: Inst Cat Salut, 1997.
  16. Álvaro T, García B. Clasificación de la Organización Mundial de la Salud de los tumores del tejido hematopoyético y linfoide. Adaptación y resumen. En: Álvaro T, Font Ll, Bosch R, Salvadó MT, Guma J.  Cuarto Curso de Hematopatología. Tortosa: Inst Cat Salut, 1997, pp: 77-125.
  17. Álvaro T; Bosch R; Salvadó M;  Barbera M; Risa R. Ausencia de correlación de p53, bcl-2 y ki 67 entre linfomas no hodgkin y neoplasias primarias múltiples. Neoplasia 1997; 14: 100-104.
  18. Andrade RE, Wick MR, Frizzera G. Immunophenotyping of hematopoietic malignancies in paraffin section. Hum Pathol 1988;19:394-402.
  19. Arber D, Weiss L. CD15: a review. Appl Immunohistochem 1993;1:17-30.
  20. Arber D, Weiss L. CD43: a review. Appl Immunohistochem 1993;1: 88-96.
  21. Arber D, Weiss L. CD5: a review. Appl Immunohistochem 1995; 3: 1-22.
  22. Arber D, Weiss L. CD57: a review. Appl Immunohistochem 1995; 3: 137-152.
  23. Arber D, Weiss L. CD10: a review. Appl Immunohistochem 1997; 5: 125-140.
  24. Armitage JO, Vose JM, Linder J, Weisenburger D, et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 1989;17:1783-1790.
  25. Banks PM, Chan J, Cleary ML, Delsol G, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637-640.
  26. Bellas C, Santón A, Plaza G. Virus Epstein-Barr (VEB) y neoplasia. en: Álvaro T, Font Ll, Bosch R, Salvadó MT, Guma J.  Cuarto Curso de Hematopatología. Tortosa: Inst Cat Salut, 1997, pp: 37-48.
  27. Bellas C, Santón A, Manzanal A, Campo E, Martín C, Acevedo A et al. Pathological, immunological, and molecular features of Hodgkin´s disease associated with HIV infection: comparison with ordinary Hodgkin´s disease. Am J Surg Pathol 1996; 20: 1520-1524.
  28. Brousset P, Imadalou K, Rubie H, Delsol-Tahou M, Selves J, Robert A, Delsol G. Paraffin-section immunohistochemistry of residual disease in the testis in patients with acute lymphoblastic leukemia using anti-mb-l/CD79a (JCB117) monoclonal antibody. Applk Immunohist 1996; 4: 56-60.
  29. Browne G, Tobin B, Carney D, Dervan P. Aberrant MT2 positivity distinguishes follicular lymphoma from reactivite follicular hyperplasia in B5- and formalin-fixed paraffin sections. Am J Clin Pathol 1991;96:90-94.
  30. Brynes RK, McCourty A, Tamayo R, Jenkins K, Battifora H. Demonstration of cyclin D1 (Bcl-1) in mantle cell lymphoma. Enhanced staining using heat and ultrasound epitope retrieval. Appl Immunohistochem 1997; 5: 45-48.
  31. Cabacadas J, Isaacson P. Phenotyping of T-cell lymphomas in paraffin sections-which antibodies? Histopathology 1991;19:419-424.
  32. Campo E; Alvaro T. El sistema inmune. Estructura y función. Pag. 59-72, en: Álvaro Naranjo, Primer Curso de Hematopatología, Tortosa, Inst. Cat. Salut, 1994.
  33. Cattoreti G, Pileri S, Parravivini C, et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993;171:83-98.
  34. Cibull M, Stein H, Gatter K, Masson D. The expression of the CD3 antigen in Hodgkin’s disease. Histopathology 1989;15:597-605.
  35. Colecchia M, Frigo B, Leopardi O. CD57 antigen. Letters to the editor. Appl Immunohistochem 1996; 4: 217-218.
  36. Coles F, Cartun R, Pastuszak W. Hodgkin’s disease, lymphocyte-predominant type: immunoractivity with B-cell antibodies. Mod Pathol 1988;1:274-285.
  37. Davey R, Elghetany M, Kurec A. Immunophenotyping of hematologic neoplasms in paraffin-embedded tissue sections. Am J Clin Pathol 1990:93(Suppl 1):S17-S26.
  38. Cossman J, Jaffe E, Fisher RI.Immunologic phenotypes of diffuse, aggressive, non-Hodgkin’s lymphomas: Correlation with clinical features. Cancer 1984;54:1310-1317.
  39. Chan JKC, Ng CS, Hui PK. A simple guide to the terminology and application of leucocyte monoclonal antibodies. Histopathology 1988;12:146-480.
  40. Chan WC. The t(2;5) or NPM-ALK translocation in lymphomas: diagnostic considerations. Advances in Anatomic Pathology 1996; 3: 396-399.
  41. Chang KL, Arber DA, Weiss LM. CD20: a review. Appl Immunohistochem 1996;4:1-15.
  42. Chetty R, Biddolph S, Kaklamanis L, Kremmer E, Cary N, Stewart S et al. Immunohistochemical demonstration of Epstein-Barr virus nuclear antigens 1 and 2 in post-transplant lymphoproliferative disorders. Appl Immunohist 1996; 4: 102-105.
  43. Chetty R, Dada MA, Gatter KC. bcl-2: Longevity personified! Advances in Anatomic Pathology 1997; 4: 134-138.
  44. Chetty R, O´Leary JJ, Gatter KC. Immunocytochemistry as a diagnostic tool. Current Diagnostic Pathology 1995; 2: 38-45.
  45. Chetty R, O´Leary JJ, Biddolph SC, Gatter KC. Immunohistochemical detection of p53 and bcl-2 proteins in Hashimoto´s thyroiditis and primary thyroid lymphomas. J Clin Pathol 1995; 48: 239-241.
  46. Chilosi M, Mobello A, Scarpa A. Combined immunohistochemical evaluation of expression of p53 antioncogene, Epstein-Barr virus and CD30 antigens in Hodgking disease and anaplastic large cell lymphomas. Patologia 1992; 25: 158A.
  47. Chilosi M, Pizzolo G. review of terminal deoxynucleotidyl transferase. Biological aspects, methods of detection and selected diagnostic applications. Appl Immunohist 1995; 3: 209-221.
  48. Chittal S, Caveriviere P, Schwarting R, et al. Monoclonal antibodies in the diagnosis of Hodgkin’s disease. The search for a rational panel. Am J Surg Pathol 1988;12:9-21.
  49. Chittal S, Al Saati T, Delsol G. Epithelial membrane antigen in hematolymphoid neoplasms. A review. Appl Immunohist 1997; 5: 203-215.
  50. Dhir RK, Nalesnik MA, Demetris AJ, Randhawa PS. Latent membrane protein expression in posttransplant lymphoproliferative disease. Appl Immunohist 1995; 3: 123-126.
  51. Dierlamm J, Pittaluga S, Wlodarska I, Stul M, Thomas J, Boogaerts M, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996; 87: 299:307.
  52. Dorfman DM, Pinkus GS. Utility of immunophenotipic studies in the diagnosis of low-grade lymphoma of MALT and other low-grade non-Hodgkin´s lymphomas of extranodal sites. Appl Immunohist 1995; 3: 160-167.
  53. Dorfman DM, Pinkus GS. CD99 (p30/32MIC2  ) immunoreactivity in the diagnosis of thymic neoplasms and mediastinal lymphoproliferative disorders. A study of paraffin sections using monoclonal antibody O13. Appl Immunohist 1996; 4: 34-42.
  54. Elghetany MT, Kurec AS, Shuehkler K, Forbes BA, Duggan DB, Davey FR. Immunophenotyping of non-Hodgking’s lymphomas in paraffin-embedded tissue sections: A comparison with genotypic analysis. Am J Clin Pathol 1991:95:517-525.
  55. Falini B, Pileri S, Stein H, et al. Variable expression of leukocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large -cell lymphoma: implications for the diagnosis between lymphoid and non-lymphoid malignances. Hum Pathol 1990;21:624-9.
  56. Fleming MD, Shahsafaei A, Dorfman DM. Absence of dendritic reticulum cell staining is helpful in distinguishing T-cell-rich B-cell lymphoma from lymphocyte predominance Hodgkin´s disease. Appl Immunohist 1998; 6: 16-22.
  57. Gaulard P, d’Agay MF, Peuchmaur M, et al Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992;140:1089-95.
  58. Gerdes J. Ki-67 and other proliferations markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990;1:199-206.
  59. González GL, Medeiros LJ, Jaffe ES. Composite lymphoma: A clinicopathologic analysis of nine patients with Hodgkin’s disease and B-cell Hodgkin’s lymphoma. Am J Clin Pathol 1991;96:81-89.
  60. Grogan, TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, Richter LC, Miller TP. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157-1160.
  61. Harris NL, Jaffe ES, Stein H et al. A Revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1359-1360.
  62. Harris NL. Diagnosis and classification of lymphomas. En Colvin RB, BhanAK, McKluskey RT. Diagnostic Immunopathology. New YorK: Raven Press, 1995:501-534.
  63. Hastrup N, Ralfkiaer E, Pallesen G. Aberrant phenotypes in peripheral T cell lymphomas. J Clin Pathol 1989;42:398-402.
  64. Hess E, Cohen C, DeRose PB, Yost BA, Costa MJ. Nonspecificity of p30/32MIC2 immunolocalization with the 013 monoclonal antibody in the diagnosis of Ewing's sarcoma: application of an algorithmic immunohistochemical analysis. Appl Immunohistochem 1997; 5: 94-103.
  65. Horning SJ, Doggett RS, Warnke RS, Dorfman RA, Fox RF, Cox RS, Levy R. Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. Blood 1984; 63:1209-1215.
  66. Ioachim HL, Dorsett B, Cronin W, Maya M, Wahl S. Acquired immunodeficiency syndrome-associated lymphomas: Clinical, pathologic, immunologic, and viral characteristics of 111 cases. Hum Pathol 1991;22:659-673.
  67. Isaacson PG, Piris MA. Splenic Marginal Zone Lymphoma. Advances in Anatomic Pathology, 1997; 4: 191-201.
  68. Jaffe ES, Zarate-Osorno, A, Medeiros LJ. The interrelationship of Hodgkin’s disease and non-Hodgkin’s lymphomas-lessons learned from composite and sequential malignances. Semin Diagn Pathol 1992;9:297-303.
  69. Jaffe ES. The role of immunophenotypic markers in the classification of non-Hodgkin’s lymphomas. Semin Oncol 1990;17:11-19.
  70. Kadin M, Muramoto L; Said J. Expression of T cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosis and mixed cellularity Hodgkin’s disease. Am J Pathol 1988;130:345-353.
  71. Kadin ME, Muramoto L, Said J. Expression of T-cell antigens on Reed-Sternberg cells in a subset of patientes with nodular sclerosing and mixed cellularity Hodgkin’s disease. Am J Pathol 1988;130:345-353.
  72. Kamel OW, Gelb AB, Shibuya RB, Warke RA. Leu7 (CD57) reactivity distinguishes nodular lymphocyte predominance Hodgkin’s disease from nodular sclerosing Hodgkin’s disease, T cell rich B cell lymphoma and follicular lymphoma. Am J Pathol 1993:142:541-6.
  73. Kamel OW, LeBrun DP, Davis RE, Berry GJ, Warnke RA. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19ª2: Correlation with Ki-67 labeling. Am J Pathol 1991;138:1471-1477.
  74. Kant JA. Molecular diagnostic approaches to lymphoid neoplasia. What´s possible and what´s useful.  Pathol Case Reviews 196; 1: 124-134.
  75. Leoncini L, Del Vecchio M, Kraft R, et al. Hodgkin’s disease and CD30-positive anaplastic large cell lymphomas-a continuous spectrum of malignant disorders. Am J Pathol 1990;137:1047-1057.
  76. Leong ASY, Milios J, Leong FJ. Epitope retrieval with microwaves. A comparison of citrate buffer and EDTA with three commercial retrieval solutions. Appl Immunohistochem 1996; 4: 201-207.
  77. Lippman SM, Miller TP, Spier CM, Slymen DJ and Grogan TM. The pronostic significance of the immunotype in diffuse large-cell lymphoma: A proposal comparative study of the T-cell and B-cell phenotype. Blood 1988;72:436-441.
  78. Lippman SM, Spier CM, Miller TP, Slymen DJ, Rybski JA, Grogan TM. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma-related to disease course. Mod Pathol 1990;3:361 -367.
  79. Medeiros L, Harmon D, Linggood R, Harris N. Immunohistologic features predict clinical behavior of orbital and conjuntival lymphoide infiltrates. Blood 1989;74:2121-2129.
  80. Medeiros LJ, Picker LJ, Gelb AB, Strickler JG, Brain SW, Weiss LM, Horning SJ, Warnke RA. Numbers of host "helper " T cells and proliferating cells predict survival in diffuse small-cell lymphomas. J Clin Oncol 1989;7:1009-1017.
  81. Ngan B, Chen-Levy Z, WeissLM, Warnke RA, Cleary M. Expression in non-Hodgkin’s lymphoma of bcl-2 protein associated with the t(14:18) chromosomal traslocation. N England J Med 1988;318:1638-1644.
  82. Norton A, Isaacson P. Lymphoma phenotyping in formalin-fixed and paraffin wax-embedded tissues: II. Profiles of reactivity in various tumor types. Histopathology 1989;14:557-579.
  83. Orazi A, Jiang B, Lee C-H, English GW, Cattoretti G, Hohn K et al. Correlation between presence of clonal rearrangements of immunoglobulin heavy chain genes and B-cell antigen expression in Hodgkin´s disease. Am J clin Pathol 1995; 104: 413-418.
  84. Pallesen G, Hamilton Ds, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin’s disease. Lancet 1991;337:320-2.
  85. Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris AL, Mason DY. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993; 22: 39-44.
  86. Pezzella F, Tse A, Cordell J, Pulford, Gatter K, Mason D. Expression of the Bcl-2 oncogene protein is not specific for 14-18 chromosomal translocation. Am J Surg Pathol 1990;137:225-232.
  87. Piris MA. Patrones inmunohistológicos básicos en las proliferaciones del ganglio linfático. En: Álvaro Naranjo T. 2º Curso de Hematopatología. Tortosa: Inst Cat Salut, 1995, pp. 69-77.
  88. Piris M, Brown DC, Gatter KC, et al: CD30 expression in non-Hodgkin’s lymphoma. Histopathology 1990;17:211-218.
  89. Prokocimer M, Shaklai M, Bassat HB, Wolf D, Goldfinger N, Rotter V. Expression of p53 in human leukemia and lymphoma. Blood 1986; 68: 113-118.
  90. Robins DB, Katz RL, Swan F Jr, Atkinson EN, Ordoñez NG, Huh YO. Immunotyping of lymphoma by Fine-needle Aspiration: a comparative study of cytospin preparations and flow cytometry. Am J Clin Pathol 1994; 101: 569-576.
  91. Scoazec JY, Berger F, Mogaud JP, Brochier J, Coiffier B, Byron P. The dendritic reticulum cell pattern in B cell lymphomas of the small cleaved, mixed and large cell types. An immunohistochemical study of 48 cases. Hum Pathol 1989;20:124-131.
  92. Schlossman SF, Boumsell, Gilks W et al. Leucocyte typing V: White cell differentiation antigens. Oxford: Oxford University Press, 1995.
  93. Schmid C, Pan L, Diss T, Issacson P. Expression of B-cell antigens by Hodgkin’s and Reed-Sternberg cells. Am J Pathol 1991;139:701-707.
  94. Schwartr BR, Pinkus G, Bacus S, Toder M, Weinberg DS. Cell proliferation in non-Hodgkin's lymphomas: Digital image analysis of Ki-67 antibody staining. Am J Pathol 1989;134:327-336.
  95. Segal GH. Assesment of B-cell clonality by the Polymerase Chain Reaction: a pragmatic overview. Advances in Anatomic Pathology 1996; 3: 195-203.
  96. Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinohasama R, Abe M, et al. Diagnosis of t(2;5) (p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994; 84: 3648-3652.
  97. Shipley WR, Hammer RD, Lennington WJ, Macon WR. Paraffin immunohistochemical detection of CD56, a useful marker for neural cell adhesion molecule (NCAM), in normal and neoplastic fixed tissues. Appl Immunohistochem 1997; 5: 87-93.
  98. Suchi T, Lennert K, Tu L, Kikuchi M, Sato E, Stansfeld AG, Feller AC. Histopathology and immunohistochemistry of peripheral T cell lymphomas: A proposal for their classification. J Clin Pathol 1987;40:995-1015.
  99. Smoller BR, Bishop K, Glusac EJ, Kim YH, Bhargava V, Warnke RA. Reassessment of lymphocyte immunophenotyping in the diagnosis of patch and plaque stage lesions of mycosis fungoides. Appl Immunohist 1995; 3: 32-36.
  100. Smoller BR, Bishop K, Glusac EJ, Bhargava V, Kim YH, Warnke RA. Lymphocyte antigen abnormalities in inflammatory dermatoses. Appl Immunohist 1995; 3: 127-131.
  101. Stein H, Mason DY, Gerdes J, et al. The expression of Hodgkin’s disease associated antigen ki-1 in reactive and neoplastic lymphoid tissue. Evidence that the Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848.
  102. Strickler JG, Copenhaver CM, Rojas VA, Horning SJ, Warnke RA. Comparison of "host cell infiltrates" in follicular lymphoma patients with and without spontaneous regression. Am J Clin Pathol 1988;90:257-261.
  103. Sun T, Susin M. Differential diagnosis of lymphoid disorders. New York: Igaku-Shoin, 1995.
  104. Sundeen JT, Longo DL, Jaffe ES. CD5 expression in B-cell small lymphocytic malignances. Correlations with clinical presentation and sites of disease. Am J Surg Pathol 1992;16:130-7.
  105. Taylor CR, Shi SR, Cote RJ. Antigen retrieval for immunohistochemistry. Status and need for greater standardization. Appl Immunohistochem 1996; 4: 144-166.
  106. Thomas G, Kay EW, Nyhan B, Leader MB. VS38c shows lack of specificity as a marker of plasma cells. Appl Immunohistochem 1997; 5: 185-188.
  107. Timens W, Boes A, Vos H, Poppema S. Tissue distribution of the C3d/EBV-receptor: CD21 monoclonal antibodies reactive with a variety of epithelial cells, medullary thymocytes and peripheral T-cells. Histochemistry 1991;95:605-11.
  108. Tsang W, Chan J. KP1 (CD68) staining of granular cell neoplasms: is KP1 a marker for lysosomes rather than the histiocytic lineage? Histopathology 1992;21:84-86.
  109. Vartanian RK, Sudilovsky D, Weidner N. Immunostaining of monoclonal antibody O13 [anti-MIC2 gene product (CD99)] in lymphomas. Impact of heat-induced epitope retrieval. Appl Immunohist 1996; 4: 43-55.
  110. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC, Martinez P. P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992; 166: 235-241.
  111. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC, Martinez P. P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992; 166: 235-241.
  112. Veloso JD, Rezuke WN, Cartun RW, Abernathy EC, Pastuszak WT. Immunohistochemical distinction of follicular lymphoma from follicular hyperplasia in formalin-fixed tissues using monoclonal antibodies MT2 and bcl-2. Appl Immunohist 1995; 3: 153-159.
  113. Vyberg M, Nielsen S. Dextran polymer conjugate two-step visualization system for immunohistochemistry. A comparison of en Vision+ with two three-step avidin-biotin techniques. Appl Immunohistochem 1998; 6: 3-10.
  114. Warnke RA, Pulford KA, Pallesen G, et al. Diagnosis of myelomonocytic and macrophage neoplasms in routinely processed tissue biopsies with monoclonal antileukocyte antibody KP1. Am J Pathol 1989;135:1089-95.
  115. Weiss LM, Strickler JG, Medeiros LJ, Gerdes J, Stein H, Warnke RA. Proliferative rates of non Hodgkin's lymphomas as assessed by Ki-67 antibody. Hum Pathol 1987;18:1155-1159.
  116. Xerri L, Bouabdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin's disease: Dissociation between immunohistochemistry and clinicopathological data. Hum Pathol 1994; 25: 449-454.
  117. Zarate-Osorno A., Medeiros LJ, Longo DL, Jaffe ES. Non-Hodgkin’s lymphomas arising in patients successfully treated for Hodgkin’s disease: A clinical, histologic, and immunophenotypic study of 14 cases. Am J Surg Pathol 1992;16:885-895.
  118. Zukerberg L, Collins A, Ferry J, Harris N. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin’s disease. Am J Pathol 1991;139:475-483.
  119. Zukerberg L, Medieros L, Ferry J, Harris N. Diffuse low grade B-cell lymphomas: four clinically distinct subtypes difined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol 1993;100:373-385.

 Volver al Índice 


[Índice]  [Marcadores]  [Linfomas_NH]  [Enf._Hodgkin]  [Prolif._histiocitarias]  [Sd. linfoprolif._esplenicos] [Extranodales] [Dg._práctico] [Bibliografía] [Iconografía]


Contenido

E-mail info@conganat.org

CopyRight Dr. Tomás Álvaro Naranjo, Dr. Ramón Bosch Príncep, Dra. Salomé Martínez González, Dra. Mª Teresa Salvadó Usach , 1998.
Última actualización: 01 noviembre 1998 22:08